Industry

Anti-VEGF treatment for wet AMD declines over 7 years

Healio Optometry1d ago1 min read

DENVER — A real-world analysis showed increased rates of undertreatment and attrition with anti-VEGF injections in patients with wet age-related macular degeneration over time, resulting in worse visual outcomes.According to a poster presented at the Association for Research in Vision and Ophthalmology meeting, the study aimed to address the knowledge gaps on the long-term impact of nonpersistence in anti-VEGF treatment on visual outcomes.“We performed a retrospective analysis of the Vestrum Health database to characterize the impact of a 6-month treatment gap in new wet AMD patients

Read full article on Healio Optometry

AI Summary

Quick Take

A retrospective analysis of the Vestrum Health database presented at ARVO reveals that patients with neovascular AMD face significant rates of treatment attrition and undertreatment over a seven-year period. These gaps in anti-VEGF therapy, specifically those lasting six months or longer, are directly correlated with a decline in visual acuity outcomes compared to consistent treatment.

Why It Matters

While clinical trials demonstrate the high efficacy of anti-VEGF therapy, real-world data consistently highlights a performance gap where patients fail to maintain those results due to the burden of frequent injections. This study underscores the long-term fragility of vision gains in wet AMD, suggesting that even a single six-month lapse can permanently alter a patient's visual trajectory. It emphasizes the need for more durable therapies or better patient support systems to combat the treatment fatigue that sets in over nearly a decade of care.

Key Findings

Retrospective data shows a progressive increase in treatment attrition and undertreatment among wet AMD patients over a 7-year follow-up period.
A treatment gap of at least 6 months was identified as a critical threshold that negatively impacts long-term visual outcomes.
The study highlights a significant disconnect between the rigorous injection schedules maintained in clinical trials and the reality of long-term patient persistence in clinical practice.

Study Snapshot

Design

Retrospective database analysis (Vestrum Health database)

Population

Newly diagnosed wet age-related macular degeneration (nAMD) patients

Practice Implications

Clinicians should proactively monitor for signs of treatment fatigue and educate patients on the specific risks of vision loss associated with even temporary gaps in therapy. Identifying patients at high risk for attrition early may allow for interventions, such as switching to longer-acting agents or implementing more robust follow-up protocols, to preserve long-term visual function.

Who's Affected

Retina SpecialistsOphthalmologistsPractice OwnersGeriatric Care Coordinators

Evidence StrengthModerate

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.